Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

Completed · Phase 3

Conditions studied: Meningococcal Immunisation (Healthy Volunteers)

In brief

Primary Objective: To demonstrate the vaccine seroresponse sufficiency of meningococcal serogroups A, C, Y, and W following the administration of a booster dose of meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine: * In Group 1 participants who were first vaccinated with 1 dose of MenACYW Conjugate vaccine 3-6 years before the booster dose. * In Group 2 participants who were first vaccinated with 1 dose of Menveo vaccine (meningococcal \[Groups A, C, Y and W135\] Oligosaccharide Diphtheria CRM197 Conjugate vaccine) 3-6 years before the booster dose. Secondary Objective: To describe: * The vaccine seroresponse, seroprotection (serum bactericidal assay using human complement \[hSBA\] titer greater than or equal to \[\>=\]1:8), and antibody responses (geometric mean titers \[GMTs\]) of meningococcal serogroups A, C, Y, and W measured using hSBA in serum specimens collected 6 days (±1 day) after vaccination in a subset of 50 participants per group (Groups 1 and 2). * The vaccine seroresponse, seroprotection (hSBA titer \>=1:8), and antibody responses (GMTs) to serogroups A, C, Y, and W measured using hSBA on Day (D)0 (pre-vaccination) and D30 (+14 days) after vaccination with MenACYW Conjugate vaccine alone (Groups 1 and 2). * The antibody persistence (GMTs and vaccine seroprotection; hSBA titer \>=1:8) of meningococcal serogroups A, C, Y, and W before a booster dose in participants who received either MenACYW Conjugate vaccine or Menveo vaccine 3-6 years earlier. * The antibody persistence (GMTs and vaccine seroprotection; hSBA titer \>=1:8) of meningococcal serogroups A, C, Y, and W in participants who received either a single dose MenACYW Conjugate vaccine (participants randomized to MET59 Groups 1, 3, and 4) or Menveo vaccine (participants assigned to MET59 Group 2), as part of study MET50, or MET43 (participants randomized to MET59 Groups 1, 3 and 4). * To describe the vaccine seroresponse, seroprotection (hSBA titer \>=1:8), and antibody responses (GMTs) to the antigens present in MenACYW Conjugate vaccine, when MenACYW Conjugate vaccine was given concomitantly with meningococcal serogroup B (MenB) vaccine (Groups 3 and 4), compared to those when it was given alone (Group 1).

Key facts

Study ID: NCT04084769
Run by: Sanofi Pasteur, a Sanofi Company
People needed: 570
Starts: 2019-09-03
Expected to finish: 2020-09-14
Last updated by the study team: 2025-09-15

Who can join

Age: 13 and older, up to 26. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Aged >= 13 to less than (<) 26 years on the day of inclusion.
Participants participated in and completed study MET50 (MET50 Groups 1, 2, or 3 only) or study MET43 (MET43 Groups 1, 2, or 3 only).
For MET59 Group 2 only (Menveo vaccine-primed participants only; enrichment population): participants had a documented record of having received 1 dose of Menveo vaccine 3-6 years earlier either as part of a clinical trial or as routine vaccination. Participants who participated in MET50 Group 4 can be enrolled if they fulfill this criterion.
Participants aged 13 to < 18 years: assent form had been signed and dated by the participant and informed consent form (ICF) had been signed and dated by the parent or guardian.
Participants aged >=18 (or legal age of majority, if different from 18 years of age) to < 26 years: ICF had been signed and dated by the participants.
Participant aged 13 to < 18 years: both the participant and parent or guardian were able to attend all scheduled visits and complied with all trial procedures.
Participants aged >=18 (or legal age of majority, if different from 18 years of age) to < 26 years: able to attend all scheduled visits and complied with all trial procedures.

You may not qualify if…

Participant was pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination. To be considered of non-childbearing potential, a female must be pre-menarche, or post-menopausal for at least 1 year, or surgically sterile.
Participation in the 4 weeks preceding the trial vaccination or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or planned receipt of any vaccine before Visit 3 (Day 30) except for influenza vaccination, which might be received at least 2 weeks before study investigational vaccine.
Receipt of immune globulins, blood or blood-derived products in the past 3 months.
Receipt of any meningococcal vaccine including a licensed or investigational MenACWY vaccine or MenB vaccine since participation in study MET50 or MET43.
Menveo vaccine-primed participants only (enrichment group for Group 2): receipt of more than 1 dose of Menveo vaccine or vaccination with another licensed or investigational MenACWY vaccine or with a licensed or investigational MenB vaccine.
Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
History of meningococcal infection, confirmed either clinically, serologically, or microbiologically.
At high risk for meningococcal infection during the trial (specifically but not limited to participants with persistent complement deficiency, with anatomic or functional asplenia, or participants travelling to countries with high endemic or epidemic disease).
Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances.
Personal history of Guillain-Barré syndrome.
Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine within at least 10 years of the proposed study vaccination.
Verbal report of thrombocytopenia, contraindicating IM vaccination.
Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination.
Current alcohol abuse or drug addiction.
Chronic illness (e.g., Human immunodeficiency viruses, hepatitis B, hepatitis C) that, in the opinion of the investigator, was at a stage where it might interfere with trial conduct or completion.
Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature >= 100.4 degree Fahrenheit). A prospective participant should not be included in the study until the condition had resolved or the febrile event had subsided.
Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.
Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where it is running

Investigational Site Number 8400012 — Birmingham, Alabama, United States
Investigational Site Number 8400005 — San Diego, California, United States
Investigational Site Number 8400013 — Bardstown, Kentucky, United States
Investigational Site Number 8400033 — Lexington, Kentucky, United States
Investigational Site Number 8400034 — Bridgeton, Missouri, United States
Investigational Site Number 8400027 — Lincoln, Nebraska, United States
Investigational Site Number 8400002 — Lincoln, Nebraska, United States
Investigational Site Number 8400004 — Lincoln, Nebraska, United States
Investigational Site Number 8400030 — Dayton, Ohio, United States
Investigational Site Number 8400028 — South Euclid, Ohio, United States
Investigational Site Number 8400009 — Norman, Oklahoma, United States
Investigational Site Number 8400038 — Erie, Pennsylvania, United States
Investigational Site Number 8400039 — Charleston, South Carolina, United States
Investigational Site Number 8400018 — Kingsport, Tennessee, United States
Investigational Site Number 8400029 — Tullahoma, Tennessee, United States
Investigational Site Number 8400031 — Kaysville, Utah, United States
Investigational Site Number 8400001 — Layton, Utah, United States
Investigational Site Number 8400014 — Layton, Utah, United States
Investigational Site Number 8400040 — Orem, Utah, United States
Investigational Site Number 8400011 — Provo, Utah, United States
Investigational Site Number 8400023 — Roy, Utah, United States
Investigational Site Number 8400003 — Salt Lake City, Utah, United States
Investigational Site Number 8400007 — Salt Lake City, Utah, United States
Investigational Site Number 8400022 — Salt Lake City, Utah, United States
Investigational Site Number 8400015 — South Jordan, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.